ID: ALA3233260

Max Phase: Preclinical

Molecular Formula: C26H31N3O6S

Molecular Weight: 513.62

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccnc(NCCCOc2ccc(C[C@@H](CC(=O)O)NS(=O)(=O)c3ccc(C)cc3)cc2)c1

Standard InChI:  InChI=1S/C26H31N3O6S/c1-19-4-10-24(11-5-19)36(32,33)29-21(17-26(30)31)16-20-6-8-22(9-7-20)35-15-3-13-27-25-18-23(34-2)12-14-28-25/h4-12,14,18,21,29H,3,13,15-17H2,1-2H3,(H,27,28)(H,30,31)/t21-/m0/s1

Standard InChI Key:  NEEFZJDFXACOOY-NRFANRHFSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 513.62

Molecular Weight (Monoisotopic): 513.1934

AlogP: 3.64

#Rotatable Bonds: 14

Polar Surface Area: 126.85

Molecular Species: ACID

HBA: 7

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.55

CX Basic pKa: 8.01

CX LogP: 1.78

CX LogD: 1.69

Aromatic Rings: 3

Heavy Atoms: 36

QED Weighted: 0.28

Np Likeness Score: -0.81

References

1. Neubauer S, Rechenmacher F, Brimioulle R, Di Leva FS, Bochen A, Sobahi TR, Schottelius M, Novellino E, Mas-Moruno C, Marinelli L, Kessler H..  (2014)  Pharmacophoric modifications lead to superpotent αvβ3 integrin ligands with suppressed α5β1 activity.,  57  (8): [PMID:24654918] [10.1021/jm500092w]

Source

Source(1):

• Scientific Literature